**Seznam publikací, PharmDr. Martin Šíma, Ph.D.**

**3.10.2018**

* Hartinger J, Novotny R, Bilkova J, Kvasnicka T, Mitas P, Šíma M, Hlubocky J, Kvasnicka J, Slanar O, Lindner J. [The Role of Dipyrone in the High Development of On-Treatment Platelet Reactivity in Acetylsalicylic Acid Treated Patients Undergoing Peripheral Artery Revascularization.](https://www.ncbi.nlm.nih.gov/pubmed/29754149) Med Princ Pract. 2018; 27(4):356-361.
* Pokorná P, Šíma M, Vobruba V, Tibboel D, Slanař O. Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation. Perfusion. 2018;33(1\_suppl):80-86.
* Pokorná P, Posch L, Šíma M, Klement P, Slanař O, van den Anker J, Tibboel D, Allegaert K. Severity of asphyxia is a covariate of phenobarbital clearance in newborns undergoing hypothermia. J Matern Fetal Neonatal Med. 2018; doi: 10.1080/14767058.2018.1432039.
* Hartinger J, Veselý P, Šíma M, Netíková I, Matoušková E, Petruželka L. 5-fluorouracil toxicity mechanism determination in human keratinocytes: *in vitro* study on HaCaT cell line. Prague Med Rep. 2017;118(4):128-138.
* Bartošová O, Bonnet C, Ulmanová O, Šíma M, Perlík F, Růžička E, Slanař O. Pupillometry as an indicator of L-DOPA dosages in Parkinson’s disease patients. J Neural Transm (Vienna). 2018;125(4):699-703.
* Šíma M, Hartinger J, Cikánková T, Slanař O. Importance of vancomycin loading doses in intermittent infusion regimens. J Infect Chemother. 2018;24(4):247-250.
* Šíma M, Bakhouche H, Hartinger J, Cikánková T, Slanař O. Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance. Eur J Hosp Pharm. 2017; doi: [10.1136/ejhpharm-2017-001396](http://dx.doi.org/10.1136/ejhpharm-2017-001396).
* Šíma M, Pokorná P, Hartinger J, Slanař O. Estimation of initial phenobarbital dosing in term neonates with moderate to severe hypoxic ischemic encephalopathy following perinatal asphyxia. J Clin Pharm Ther. 2018; 43(2):196-201.
* Šíma M, Hartinger J, Cikánková T, Slanař O. Estimation of once-daily amikacin dose in critically ill adults. J Chemother. 2018; 30(1):37-43.
* Šíma M, Vodička M, Marešová V, Šálek T, Čabala R, Slanař O. Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. Int J Clin Pharm. 2017; 39(5):1095-1100.
* Šíma M, Hartinger J, Rulíšek J, Šachl R, Slanař O. Meropenem-induced valproic acid elimination: a case report of clinically relevant drug interaction. Prague Med Rep. 2017;118(2-3):105-109.
* Šíma M, Hartinger J, Štenglová Netíková I, Slanař O. Creatinine clearance estimations for vancomycin maintenance dose adjustments. Am J Ther. 2018;25(5):e602-e604.
* Šíma M, Hronová K, Hartinger J, Slanař O. A simulation of loading doses for vancomycin continuous infusion regimens in intensive care. Infect Dis. 2017; 49(9):674-679.
* Pokorná P, Hronová K, Šíma M, Slanař O, Klement P, van den Anker JN, Tibboel D. Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review ans case report. Eur J Clin Pharmacol. 2017;73(5):647-649.
* Šíma M, Pokorný M, Paďour F, Slanař O. Terlipressin induced severe hyponatremia. Prague Med Rep. 2016; 117(1):68-72.
* Šíma M, Pokorná P, Hronová K, Slanař O. Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. Physiol Res. 2015;64(4\_suppl):513-9.
* Hronová K, Šíma M, Světlík S, Matoušková O, Slanař O. Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol. 2014;7(6):821-35.
* Šíma M, Slanař O. Pharmacological importance of orphan nuclear receptors. Cesk Fysiol. 2014;63(1):19-24.
* Šíma M, Netíková I, Slanař O. Pregnane xenobiotic receptors and their effect on drug elimination from the organism. Prague Med Rep. 2013;114(4):205-13.
* Holas T, Vávrová K, Šíma M, Klimentová J, Hrabálek A. Synthesis and transdermal permeation-enhancing aktivity of carbonate and carbamate analogs of Transkarbam 12. Bioorg Med Chem. 2006;14(23):7671-80.